Kura Oncology, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 42.79 million compared to USD 33.11 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 0.49 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.71 USD | -0.29% | +0.39% | +44.02% |
May. 02 | Transcript : Kura Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.02% | 1.58B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023